MannKind | MNKD - DEBITO





DEBITO Cambiamento Data
Adma Biologics USD 83.12M 702K 2025-09
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
Eli Lilly USD 42.5B 3.6M 2025-12
Halozyme Therapeutics USD 2.14B 2.01M 2026-03
Insmed USD 727.62M 275K 2026-03
Karyopharm Therapeutics USD 299.23M 35.14M 2025-12
MacroGenics USD 37.01M 238K 2025-09
MannKind USD 367.44M 247.53M 2025-12
Merck USD 49.34B 7.97B 2025-12
Minerva Neurosciences USD 0 0 2024-09
Novavax USD 233.31M 4.23M 2024-09
Novo Nordisk DKK 118.72B 15.94B 2025-03
Pfizer USD 63.73B 231M 2026-03
Sanofi EUR 20.33B 1.43B 2025-12
Xencor USD 187.75M 118.48M 2025-12